Statins and Fibrates in Age-Related Macular Degeneration: A Contemporary Clinical Narrative Review (2020–2025)
Journal of Clinical Medicine · 14.04.2026 · 15 (8) · 2960
DOI: 10.3390/jcm15082960 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 14.04.2026. Verfasst von Weronika Dmoch und 5 weiteren Autor:innen. Beteiligte Einrichtung: Ophthalmology Student Research Group, Department of Ophthalmology, Medical University of Warsaw, 4 Lindleya Street, 02-005 Warsaw, Poland. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Age-related macular degeneration (AMD) remains the leading cause of irreversible central vision loss in the elderly. Increasing attention has been directed toward lipid metabolism as a potential contributor to disease onset and progression. The overlap between AMD and atherosclerosis—particularly regarding lipid accumulation, endothelial dysfunction, and chronic inflammation—has prompted interest in lipid-lowering therapies. This narrative review synthesizes the clinical evidence published between 2020 and 2025 on the potential role of statins and fenofibrate in AMD risk modification and disease progression. A structured literature search was conducted in PubMed, Scopus, and Web of Science using combined MeSH and free-text terms related to lipid-lowering agents and AMD. Human studies evaluating clinical incidence or progression outcomes were considered alongside contextual evidence from prior evidence syntheses. Overall, findings remain heterogeneous. Most studies did not demonstrate a consistent association between statin therapy and AMD incidence or progression in unselected populations. However, selected reports suggested a potential delay in dry AMD onset or slower disease progression among patients receiving prolonged or higher-intensity statin treatment. Evidence regarding fenofibrate was more limited and heterogeneous, with only a tentative protective signal observed in adherent users, particularly for non-exudative AMD. The current literature does not support lipid-lowering therapy as a universal preventive strategy for AMD. Nonetheless, subgroup-specific benefits cannot be excluded, especially in early disease stages or metabolically high-risk populations. Further well-designed prospective and randomized studies are needed to clarify therapeutic relevance and identify the patients who are most likely to benefit.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ophthalmology Student Research Group, Department of Ophthalmology, Medical University of Warsaw, 4 Lindleya Street, 02-005 Warsaw, Poland.
- Department and Clinic of Ophthalmology, University Clinical Center, Medical University of Warsaw, 4 Lindleya Street, 02-005 Warsaw, Poland.
ORCID-Profile: Weronika Dmoch, Julia Sawicka, Natalia Żelichowska, Piotr Maciejewicz
Zitieren
APA
Dmoch, W., Sawicka, J., Żelichowska, N., Kępczyńska, Z., Maciejewicz, P., & Kęcik, D. (2026). Statins and Fibrates in Age-Related Macular Degeneration: A Contemporary Clinical Narrative Review (2020–2025). Journal of Clinical Medicine, 15(8), 2960. https://doi.org/10.3390/jcm15082960
Vancouver
Dmoch W, Sawicka J, Żelichowska N, Kępczyńska Z, Maciejewicz P, Kęcik D. Statins and Fibrates in Age-Related Macular Degeneration: A Contemporary Clinical Narrative Review (2020–2025). Journal of Clinical Medicine. 2026;15(8):2960. doi:10.3390/jcm15082960
BibTeX
@article{Dmoch2026,
author = {Dmoch, Weronika and Sawicka, Julia and Żelichowska, Natalia and Kępczyńska, Zuzanna and Maciejewicz, Piotr and Kęcik, Dariusz},
title = {Statins and Fibrates in Age-Related Macular Degeneration: A Contemporary Clinical Narrative Review (2020–2025)},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {8},
pages = {2960},
doi = {10.3390/jcm15082960}
}
EUVIMED